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3ABSTRACT
Transferrin is the major iron binding protein in human plasma. It binds iron with high
affinity in a redox inactive form and delivers it to growing cells. Each molecule is
capable of binding two molecules of ferric iron. Normally, transferrin is only about 30%
saturated with iron. In certain clinical conditions, the iron concentration in serum is
increased so that the iron binding capacity is exceeded and non-transferrin-bound iron
(NTBI) is formed in serum. NTBI is potentially toxic because it generates free radical
formation and can be taken up by tissues, leading to excess deposits that can potentiate
tissue damage. It is also known that iron enhances the growth of bacteria and fungi, and
can predispose patients to septic infections.
This thesis describes the development of an efficient process for producing
pharmaceutical grade iron-free apotransferrin. The biochemical efficacy of
apotransferrin for iron binding therapy was studied in early phase clinical trials in
haematological stem cell transplant (SCT) patients. The scope of this work did not
include studying the clinical efficacy of apotransferrin.
The manufacturing method used fraction IV of the Cohn cold ethanol human plasma
fractionation process as starting material. Apotransferrin was purified in two ion
exchange chromatography steps and ultrafiltration with over 90% recovery. In order to
obtain a virus-safe product, the process comprised solvent detergent treatment as the
main virus inactivation step and virus filtration and polyethylene glycol precipitation to
remove physico-chemically resistant infectious agents. The purity of the product was at
least 98%, main impurities being IgG, IgA and hemopexin. Methods for studying the
iron binding capacity, the transferrin conformation and its iron forms, and the
glycosylation variants were developed and used to study the quality of the finished
product batches. The product had intact iron binding capacity and a native
conformation. The results of several production batches indicated that the
manufacturing could be carried out reproducibly. Product characterisation by
electrospray and MALDI-TOF mass spectrometry indicated no other chemical
modifications than N-linked glycan chains and disulphide bonds, except minor
oxidation. A stable liquid formulation suitable for intravenous infusion was developed.
The biochemical binding of NTBI to apotransferrin in vivo was studied by several
methods. The bleomycin method for NTBI determination was modified for microwell
measurement and evaluated. The bleomycin assay was reproducible and NTBI was
found in serum samples only when transferrin saturation was >80% and haemolysed
samples were excluded. The bleomycin assay that measures redox-active iron
underestimated the true concentration of NTBI. The concentration of NTBI could be
calculated from the shift of transferrin iron forms found in vivo after intravenous
4infusion of apotransferrin to patients. It could also be determined with a chelation based
method, which, however, had a lower specificity than the bleomycin method. In
haematological SCT patients, the concentration of NTBI could be as high as 20 µmol/l.
Apotransferrin given in single intravenous doses to six patients bound NTBI effectively,
although in most cases temporarily. With repeated high dose regimens, the appearance
of NTBI was prevented in 5 of 8 patients.
The influence of NTBI on the growth of the opportunistic pathogen Staphylococcus
epidermidis was studied both with purified transferrin and in serum milieu. In both
cases, growth was critically dependent on NTBI and on a high transferrin saturation.
Only at high initial bacterial concentrations could growth be detected with partially
saturated transferrin. Apotransferrin administered to SCT patients bound NTBI and
restored the growth inhibitory effect of serum. Exogenous apotransferrin might protect
the patients against infections by S. epidermidis and other opportunistic pathogens
whose growth is dependent on NTBI.
In conclusion, the apotransferrin was pure and safe and showed in vivo the biochemical
effects that could be expected of a functional human apotransferrin product. In SCT
patients it was possible to prevent the appearance of NTBI and maintain the bacterial
growth inhibitory effect in serum.
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INTRODUCTION
1 Transferrin and serum iron
1.1 Transferrin characteristics
Transferrins represent a class of proteins found in biological fluids of all vertebrates and
invertebrates with the property of reversibly binding iron. The name transferrin was
suggested by Holmberg and Laurell (1947) and is used as the name for the iron-binding
β-globulin found in blood serum and other extracellular fluids of vertebrates (de Jong et
al., 1990). Other proteins of the same group are lactoferrin in milk and in neutrophil
granules (Metz-Boutigue et al., 1984), ovotransferrin of egg white and
melanotransferrin (antigen p97) produced by melanoma cells (Brown et al., 1982).
Transferrin was first detected and isolated in works described by Holmberg and Laurell
(1945) and Schade and Caroline (1946). The latter group used the newly developed
Cohn fractionation procedure to prepare the iron-binding fraction of plasma. Since then,
the protein has been thoroughly studied and characterised (de Jong et al., 1990; Evans et
al., 1999; Harris and Aisen, 1989).
Human transferrin is a single polypeptide chain containing 679 amino acid residues
(MacGillivray et al., 1983). The protein has 19 disulphide bridges. Crystallographic
studies have shown that the transferrin molecule is organised into two homologous
lobes of about 330 amino acid residues, the N- and the C-lobe. The lobes are linked by a
short flexible spacer peptide and each lobe contains two dissimilar domains divided by a
cleft which is the binding site for Fe3+ (Bailey et al., 1988; Wang et al., 1992) (Figure
1). At the iron binding site, four of the six Fe3+ co-ordination sites are occupied by the
protein ligands (2 tyrosine, 1 histidine and 1 aspartate residue) and two by the bidentate
carbonate anion (Bailey et al., 1988; Hirose, 2000). The synergistic binding of an anion,
preferentially the carbonate molecule, is essential for the iron binding (Harris and Aisen,
1989).
Two N-linked oligosaccharides are found in the C-lobe at aspargine residues Asn413 and
Asn611. The carbohydrates constitute about 6% of the mass of transferrin that has a
molecular weight of 79750. The glycan chains are mainly biantennary (85%) and
triantennary (15%) complex-type glycans (Fu and van Halbeek, 1992; Spik et al., 1985).
The number of sialic acid residues per transferrin molecule is between 4 and 6.
Glycosylation variants occur in different conditions. In patients suffering from
alcoholism, carbohydrates lacking two to four of the terminal trisaccharides, comprising
the negatively charged sialic acid and the neutral N-acetylglucosamine and galactose
have been found, and disialotransferrin and to a lesser degree mono- and
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asialotransferrin are present (Stibler, 1991). Such carbohydrate-deficient transferrin can
be used as a marker for alcoholism (Turpeinen et al., 2001). Increase of branching has
been found during pregnancy (Leger et al., 1989) and in congenital glycosylation
disorder, when there also is an increase in fucosylation (Mills et al., 2001; Yamashita et
al., 1993). The variation of glycosylation is a determinant of the microheterogeneity of
transferrin. Another determinant is the genetic polymorphism. Genetic variants were
first detected by starch electrophoresis. The most common was designated TfC, the
more anodal TfB and cathodal TfD. Variants within the subgroups have been identified
with isoelectric focusing (Kamboh and Ferrell, 1987). Of at least 38 variants, only 4
occur with a frequency over 1% (de Jong et al., 1990). Among Caucasians, the C
variant, having several subtypes including C1, C2 and C3, is found almost exclusively
(Tenkanen et al., 1989). A single amino acid substitution determines the TfC1 and TfC2
variants (Namekata et al., 1997). The highest frequencies of the D variant is found
among African blacks, although hardly ever as homozygous D phenotypes (Kasvosve et
al., 2000). Attempts to establish a relationship between the transferrin variant, serum
transferrin concentration, and iron-binding capacity in Caucasians have been
inconclusive (Sikstrom et al., 1993). A functional difference was demonstrated between
CD and CC phenotypes in blacks, with a lower in vitro binding of iron to transferrin for
the CD individuals and differences in serum iron parameters between the phenotypes
(Kasvosve et al., 2000). In a transferrin variant where an amino acid substitution in the
C-lobe leads to an open structure of the iron saturated molecule, a reduced affinity for
the transferrin receptor was found (Evans et al., 1994b).
Each molecule of transferrin can bind two Fe3+ ions. The four iron forms of transferrin
are the iron-free apotransferrin, the monoferric transferrins with iron in the C- or the N-
lobe, respectively, and the diferric holotransferrin. The affinity for iron at physiological
pH 7.4 is high, with a binding constant of about 1022 (Harris and Aisen, 1989). Upon
binding of iron, the lobes undergo a conformational transition from the apo-structure
with an open interdomain cleft to a closed holo-structure (Hirose, 2000). The
conformational change can be studied by urea polyacrylamide gel electrophoresis first
described by (Makey and Seal, 1976), whereby the different iron forms of transferrin
can be resolved. The presence of urea causes the lobes that do not contain iron to unfold
and decreases their mobility (Evans and Williams, 1980). It is believed that the change
in conformation is important for the binding of the molecule to the transferrin receptor,
and diferric transferrin has a 10-100 times higher affinity for the receptor than
apotransferrin (Richardson and Ponka, 1997). The binding mechanism of transferrin to
its receptor is not fully elucidated, but it is believed that the recognition site requires the
presence of both transferrin lobes (Mason et al., 1997; Mason et al., 2002; Zak et al.,
2002) and that the glycans are of less importance (Hoefkens et al., 1997). In circulation,
where normally only a third of the transferrin iron binding sites are occupied, iron
preferentially binds to the N-terminal lobe which is also called the acid labile lobe
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(Evans et al., 1999). The metal release from transferrin is mainly accomplished by a
decrease in pH, where protonation of the iron ligands causes release of the iron. The
iron release can also be accelerated by other chemical compounds capable of
complexing iron such as pyrophosphates (Morgan, 1979) and citrate (Gumerov et al.,
2003). Transferrin is capable of binding several other metals, but with a lower affinity
(Harris and Aisen, 1989).
Figure 1. A ribbon diagram of a diferric rabbit serum transferrin molecule. The arrow indicates the
position of the Fe3+ molecule in the inter-domain cleft in the N-lobe. The model is based on the PDB
atomic coordinate file 1JNF (Hall et al., 2002).
1.2 Iron and role of transferrin
Iron is essential for virtually all living organisms. It is needed in proteins for oxygen
transportation and for enzymes that can catalyse redox reactions and DNA synthesis. In
biological systems and aqueous solutions, the transition metal iron can exist in two
oxidative states as ferrous (Fe2+) or ferric iron (Fe3+), capable of respectively donating
or accepting electrons. In aerobic conditions, Fe2+ is oxidised to Fe3+, which is the most
common form found in the environment. The properties of iron are associated with two
types of problems. First, Fe3+ is highly insoluble at physiological pH. With increasing
pH, Fe3+ readily hydrolyses to hydroxy-forms, followed by irreversible formation of
hydroxy-iron polymers that precipitate. At physiological pH 7, the solubility of Fe3+ is
only about 10-18 mol/l (Spiro and Saltman, 1974). Secondly, the redox active iron can be
N-lobe
C-lobe
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toxic as it is capable of forming harmful free radicals (Halliwell and Gutteridge, 1985).
Ferrous iron catalyses the formation of the highly oxidising hydroxyl radical (OH⋅) from
hydrogen peroxide, known as the Fenton reaction (1). Ferric iron can be reduced to
ferrous iron by superoxide (O2-). This net reaction (2) is referred to as the Haber-Weiss
reaction. However, the term "Fenton-catalysed Haber-Weiss reaction" often used to
describe these reactions, has been criticised. In vivo, the superoxide is mainly
considered to be the source of hydrogen peroxide for the Fenton reaction, and other
agents as well as superoxide can reduce iron. Toxicity therefore arises from the Fenton
reaction alone, and the Haber-Weiss reaction probably does not take place (Koppenol,
2001).
Fe2+ + H2O2 → Fe3+ + OH- + OH⋅ (1)
O2- + H+ + H2O2 → O2 + OH⋅ + H2O (2)
The hydroxyl radical is, although short-lived, highly reactive and able to cause
secondary radicals and initiate the lipid peroxidation chain reaction. It also causes DNA
strand breaks, inactivates enzymes and can depolymerise polysaccharides (McCord,
1998).
In the blood stream, iron is transported to the cells bound to transferrin. This type of
iron transportation brings several benefits. First, the transferrin is only about 30%
saturated with iron to ensure capacity to sequester available iron. Second, iron is kept in
a redox-inactive form. It has been shown that transferrin-bound iron is not capable of
promoting hydroxyl radical formation (Baldwin et al., 1984). Third, iron is not
hydrolysed as it would be if were in the form of a free salt and can be targeted directly
to cells requiring iron. Transferrin-bound iron is taken up by the cells by receptor-
mediated endocytosis (Richardson and Ponka, 1997) whereafter apotransferrin is re-
circulated to the blood stream.
Iron is used for the synthesis of proteins requiring iron for biological activity, or stored
in intracellular ferritin. Several other iron-binding proteins are involved in the human
iron metabolism. Although transferrin is of utmost importance in the transportation of
iron, the ∼3-4 mg of transferrin-bound iron is only ∼0.1% of the total body iron of
∼4000 mg. However, the transferrin iron turnover is significant and about 30 mg of iron
is transported daily to the cells. Of this, about 80% is transported to the bone marrow for
haemoglobin synthesis in developing erythroid cells. Haemoglobin iron comprises 60-
70% of body iron, followed by the intracellular storage protein ferritin that holds 10-
20% of iron. The rest of the iron is found in myoglobin, cytochromes and iron-
containing enzymes. Body iron stores are highly conserved, only 1-2 mg is lost daily
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and the iron balance is maintained by dietary iron absorption (Conrad and Umbreit,
2000; Fairbanks and Beutler, 1995).
1.3 Serum non-transferrin-bound iron (NTBI)
In certain clinical conditions, the iron concentration in serum is increased. If the iron
binding capacity of transferrin is exceeded, non-transferrin-bound iron (NTBI) can form
in serum. The reasons for the increase of iron are diverse (Table 1). Although the causes
of NTBI vary, it is generally considered that the presence of NTBI is a pathological
manifestation and is never found in healthy individuals (Breuer et al., 2000a). NTBI
was first detected in chronic iron overload disorders such as haemochromatosis. It can
also be detected in acute events such as for haematological patients undergoing
myeloablative conditioning therapy, and especially those who receive stem cell
transplants (SCT) (Bradley et al., 1997; Sahlstedt et al., 2001). The myeloablative
conditioning therapy results in a halt of erythropoiesis, the only effective way of
transferrin iron utilisation. If iron release to circulation continues from macrophages
taking up senescent erythrocytes, this results in a remarkable increase in the total serum
iron level.
The form and nature in which NTBI exists in serum is not fully elucidated (Esposito et
al., 2002; Hider, 2002). Primarily, the formation of NTBI was considered a spillover
phenomenon when the transferrin saturation was exceeded. According to (Grootveld et
al., 1989), a significant portion of NTBI in haemochromatosis is in the form of citrate
and, possibly, acetate complexes. The tendency of iron to form large iron-polymers at
physiological conditions could lead to different types of iron-citrate complexes, varying
in size from monomeric to large oligomer complexes with even 17-19 iron molecules
(Hider, 2002). Albumin could also act as an iron binding ligand due to the presence of
large number of negatively charged carboxylate sites (He and Carter, 1992). In a study
using pure albumin, it was found that albumin had capacity to bind added iron which
resulted in inhibition of lipid peroxidation (Loban et al., 1997). Studies with
hypotransferrinaemic mice have indicated a mixture of iron species with differing
reactivity to NTBI assays (Simpson et al., 1992). The concentrations varied in the range
of 1-20 µmol/l depending on the assay used to measure NTBI. No detectable
mononuclear iron was measured by electron paramagnetic resonance spectrometry,
indicating lack of citrate-bound iron in monomeric form. Thus, NTBI is probably a
mixture of different forms of iron bound to extracellular components, and the
proportions of the iron forms may vary between patient groups and clinical conditions.
NTBI is potentially toxic because it generates free radical formation and can be taken up
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Table 1. Examples of clinical conditions when NTBI has been detected in serum.
Clinical condition Suggested mechanism for formation of NTBI Reference
Haemochromatosis Increased iron absorption from the diet leads to
iron accumulation and overload
(Grootveld et al., 1989)
Secondary iron overload
disorders (including
thalassemia)
Multiple: Ineffective erythropoiesis, red cell
transfusions, increased intake or absorption of
iron
(Bottomley, 1998;
Hershko et al., 1978)
Chemotherapy of
haematologic
malignancies
Drug-induced halt of erythropoiesis and
strongly decreased uptake of transferrin iron
(Bradley et al., 1997;
Carmine et al., 1995;
Harrison et al., 1994;
Sahlstedt et al., 2001)
Premature and full-term
neonates
Ferro-oxidase deficiency, low transferrin
concentration, accelerated erythrocyte turnover
(Evans et al., 1992);
(Lindeman et al., 1992);
(Lindeman et al., 2000)
Cardiopulmonary bypass Haemolysis (Pepper et al., 1995)
Haemodialysis patients Intravenous iron infusion (Breuer et al., 2000b;
Parkkinen et al., 2000)
Fulminant liver failure Possible release of iron from damaged liver
cells
(Evans et al., 1994a)
Atransferrinemia Low levels of transferrin (Simpson et al., 1992)*
(Beutler et al., 2000;
Craven et al., 1987;
Hamill et al., 1991)
*NTBI detected in hypotransferrinaemic mice
by tissues, leading to excess deposits that can potentiate tissue damage. NTBI is taken
up by cells by a transferrin independent transport system which is rapid, but not
regulated in the same manner as the transferrin receptor system and may involve a
lipocalin transport mechanism (Kaplan, 2002). It is mainly taken up by parenchymal
cells (Craven et al., 1987), particularly in the liver (Brissot et al., 1985) and there are
several lines of evidence suggesting that NTBI is toxic to liver cells (Anderson, 1999).
Ferric iron causes cytotoxicity already after a few hours in liver cell cultures (Morel et
al., 1990; Sakurai and Cederbaum, 1998) and it also rapidly impairs the phagocytic
activity of polymorphonuclear leukocytes (van Asbeck et al., 1984). Most of the toxic
effects of the redox-active NTBI are believed to take place intracellularly, when iron
accumulates and the cellular defence mechanism is overwhelmed. On the other hand,
sera of leukaemia patients has been shown to induce lipid peroxidation. NTBI could
thus damage cells even without uptake into the cells (Carmine et al., 1995). Because it
appears that NTBI may damage various cell types, it is possible that NTBI plays a part
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in the pathogenesis of mucosal and liver injury associated with high-dose chemotherapy
(Beare and Steward, 1996; Carmine et al., 1995).
1.4 Measurement of NTBI in serum
A number of methods have been developed to measure NTBI in serum. A prerequisite
for the determination is to avoid interference of iron bound in redox-inactive form to
transferrin or ferritin, or to therapeutic chelating agents such as desferrioxamine.
Hershko et al. (1978) were the first to describe a method to measure NTBI, where the
iron was mobilised with a chelating agent (EDTA) and after ultrafiltration, the chelated
iron complex in the ultrafiltrate was measured. Several methods based on a similar
chelation principle before quantitation have been described (Table 2). Nitrilotriacetate
(NTA) is mostly used for iron chelation (Figure 2).
In the bleomycin-detectable iron assay iron is not chelated before determination, but is
bound in its ferrous form to the glycopeptide antibiotic bleomycin (Figure 2). Ascorbic
acid is added as a reduction agent. The formed iron-bleomycin undergoes complex
autooxidation which results in the release of the reactive hydroxyl radical (Sugiura et
al., 1982). The hydroxyl radicals damage added DNA and results in the release of
malondialdehyde. The amount of bleomycin-iron is proportional to the degree of DNA
degradation (Evans and Halliwell, 1994). Malondialdehyde, formed from deoxyribose
residues of DNA, can be measured by the thiobarbituric acid test (Gutteridge et al.,
1981), which is the most widely used quantitation method. An alternative quantitation
method has been described by Burkitt et al. (2001) where an ethidium-binding assay
was used to measure DNA degradation. The bleomycin assay has been compared with
another biochemical assay based on the activation of the iron free aconitase enzyme in
presence of NTBI (Mumby et al., 1998). Both biochemical methods have given similar
results. The bleomycin-detectable iron assay has been used to study the occurrence of
NTBI in various clinical conditions and biological fluids (Halliwell and Gutteridge,
1990).
In patients with haematologic malignancies, NTBI has been studied both with the
bleomycin assay and with the chelation method. The reported NTBI concentrations vary
depending on the method for determination, and it is difficult to conclude the true
concentration of NTBI based on these results. The highest reported bleomycin-
detectable iron concentrations of 21.5 and 28 µmol/l were found by Halliwell et al.
(1988) and Harrison et al. (1994), respectively. In these studies, an early version of the
bleomycin method was used (Gutteridge et al., 1981). In the early version, the TBA-
chromogen was measured directly in the reagent mixture and not extracted into butanol.
It is possible that interfering compounds remained in the mixture. Carmine et al. (1995)
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measured much lower concentrations in the range of 0.1 – 1 µmol with the bleomycin
assay. Bradley et al. (1997) used the chelation method with NTA and HPLC
quantitation of the chelated iron-complex that gave NTBI values up to 5 µmol/l. Similar
values (2-7 µmol/l) were obtained by Durken et al. (1997) when NTA-complexed iron
was quantified by atomic absorption spectrophotometry.
Table 2. Assays for measurement of serum NTBI
Assay type Quantitation of iron Reference
1. Chelation of NTBI
Chelation of NTBI with EDTA,
ultrafiltration of complex
Colorimetric (Hershko et al., 1978)
Chelation of NTBI with NTA,
ultrafiltration of complex
HPLC (Porter et al., 1996; Singh
et al., 1990)
Colorimetric using
bathophenanthroline chromogen
(Gosriwatana et al., 1999;
Zhang et al., 1995)
Atomic absorption
spectrophotometry
(Durken et al., 1997;
Gosriwatana et al., 1999;
Jakeman et al., 2001)
Chelation of NTBI with oxalate,
transfer of oxalate to immobilised
desferrioxamine
Fluorescence using metallosensor
calcein
(Breuer et al., 2000b)
Chelation of NTBI with
desferrioxamine
Fluorescence quenching of
fluorescein-desferrioxamine probe
(Breuer et al., 2001; Breuer
and Cabantchik, 2001)
2. Biochemical reactions caused by NTBI
Bleomycin assay. Ferrous iron
complexed with bleomycin causes
DNA degradation, degradation
products are measured.
Thiobarbituric acid reaction,
spectrophotometry
(Evans and Halliwell, 1994;
Gutteridge et al., 1981;
Gutteridge and Hou, 1986)
Ethidium-binding assay (Burkitt et al., 2001)
Activation of iron-sulphur cluster
of aconitase
Enzymatic (Mumby et al., 1998)
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Figure 2. A schematic representation comparing a serum transferrin iron and two NTBI assay methods.
The double circles represent the transferrin molecule with two lobes, each capable of binding one iron
molecule.
A, A chromogenic method measuring transferrin-bound iron. The iron is released from transferrin by
acidification and reduced. Ferrous iron reacts with the chromogenic agent which can be either Ferene-S or
Ferrozine and the coloured complex is measured by spectrophotometry.
B, The bleomycin assay measuring NTBI. The bleomycin reacts with NTBI in the sample after reduction
using ascorbate. The bleomycin-iron complex undergoes complex autooxidation which results in the
release of the reactive hydroxyl radical (OH⋅). The hydroxyl radicals damages the added DNA and results
in the release of malondialdehyde. This reacts with thiobarbituric acid (TBA) and forms a pink
chromogen, which after extraction into butanol is measured by spectrophotometry.
C, The chelation assay measuring NTBI. The chelator nitrilotriacetate (NTA) is added to the sample to
chelate NTBI. The chelated iron is separated from transferrin and other serum proteins by ultrafiltration.
The iron is complexed after reduction using bathophenantroline, and measured by spectrophotometry.
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2 Iron and infection
2.1 NTBI, microbial growth, and risk of infection
Like all living organisms, microbes are dependent on iron for growth, with the
exception of some lactic acid bacteria (Archibald, 1983). The low availability of iron in
vivo restricts the growth of invading bacteria. This mechanism, often described as the
iron withholding system (Weinberg, 1984), is important in the defence against
infections. It was first demonstrated by Schade and Caroline (1944), who showed that
raw hen egg white inhibited the growth of several bacterial strains and that this
inhibition could be overcome by addition of iron. Later this effect was ascribed to the
ovotransferrin in egg white, and a similar mechanism was found in serum (Schade and
Caroline, 1946).
To overcome the iron-limiting conditions, pathogenic bacteria have evolved specific
high affinity iron-uptake mechanisms to acquire iron from the host. Pathogenic
neisseriae and Haemophilus influenza (Gray-Owen and Schryvers, 1996; Schryvers and
Stojiljkovic, 1999) possess surface receptors that directly bind transferrin. Receptors
that specifically bind lactoferrin, haemoglobin, or haem have also been found
(Wandersman and Stojiljkovic, 2000). Another mechanism whereby bacteria and fungi
can acquire iron from the host is through synthesis and excretion of low-molecular-
weight compounds that chelate iron with high affinity; these are known as siderophores.
Siderophores are produced by many, both pathogenic and non-pathogenic micro-
organisms, in response to a deficiency of iron and may even sequester iron attached to
molecules such as transferrin, lactoferrin, and ferritin. The sequestered iron is taken up
via siderophore receptors on the cells. Well characterised siderophore systems are found
in enteric gram-negative bacteria Escherichia, Klebsiella, and Salmonella (Griffiths and
Williams, 1999). Siderophores are also produced by gram-positive bacteria; e.g.
Staphylococcus aureus (Trivier and Courcol, 1996) and pathogenic fungi (Howard,
1999). The ability to produce siderophores in vitro is not, however, necessarily
associated with an increased virulence of the bacteria (Griffiths and Williams, 1999;
Ratledge and Dover, 2000). The siderophore may not be able to effectively dissociate
iron from the iron-binding proteins, or the iron-siderophore complex may not
necessarily be transported back to the organism. However, for some bacterium as for the
opportunistic pathogen Pseudomona aeruginosa, it has been shown in vivo through an
animal model that the siderophore pyoverdin was essential for the virulence (Meyer et
al., 1996).
The virulence of many organisms has been considerably enhanced in experimental
infections by injecting iron compounds into an animal host (Griffiths, 1999). Clinical
conditions with iron overload have been associated with an increased risk of infection.
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Vibrio vulnificus is an example of an opportunistic bacterium that causes infections in
patients with haemochromatosis (Bullen et al., 1991). A risk for Yersinia enterocolita
septicaemia is clearly associated with iron overload disorders, especially when
desferrioxamine is used for iron chelation (Bottone, 1997; Mofenson et al., 1987).
Lambert and Hunter (1990) suggested that high transferrin saturation might contribute
to lethality of pneumococcal pneumonia.
Haematological patients receiving high-dose chemotherapy and stem cell
transplantation have an increased risk for infections which can be life-threatening. In
addition to neutropenia as the major host defence defect, the use of central venous
catheters, severe mucositis and increased rates of antibiotic resistant pathogens are
recognised risk factors (Ehni et al., 1991; Elishoov et al., 1998; Gonzalez-Barca et al.,
1996). Hospital-derived gram-positive infections have become more common during the
last two decades (Zinner, 1999), predominated by coagulase negative staphylococci
(Wade et al., 1982; Winston et al., 1983). Also fungal infections (candidiasis and
aspergillosis) are common (Jantunen et al., 1997; Morrison et al., 1993). It has been
speculated that the increased rate of infections in this patient group also could be related
to the high serum iron concentrations with highly saturated transferrin. Caroline et al.
(1969) proposed that high transferrin saturation predisposed patients with acute
leukemia to infections by the yeast Candida albicans. An association between the high
transferrin saturation and bacterial growth was described by Hunter et al. (1984), who
showed that serum from leukemic patients had a reduced ability to inhibit the growth of
Pseudomonas aeruginosa. A similar in vitro effect was found for Escherichia coli and
Staphylococcus aureus (Gordeuk et al., 1986). High transferrin saturation level was
proposed as a possible risk factor for systemic fungal infections in patients with
haematological malignancies (Iglesias-Osma et al., 1995; Karp and Merz, 1986).
The presence of NTBI may therefore be a contributing virulence factor to opportunistic
bacteria and fungi, and may predispose these immunocompromised patients to
infections and septicaemia (Ward and Bullen, 1999). Binding of NTBI into a redox-
inactive form could possibly decrease the high infection risk in the patients. Several
studies have shown that transferrin displays a growth inhibitory effect in vitro on
opportunistic organisms, such as Vibrio vulnificus (Chart and Griffiths, 1985), Rhizopus
(Boelaert et al., 1993), Candida albicans (Caroline et al., 1969; Shiraishi and Arai,
1979) and Histoplasma capsulatum (Sutcliffe et al., 1980). Recently, an
anticryptococcal protein in serum was identified as apotransferrin (Sridhar et al., 2000).
Iron chelating agents, such as the most widely used intravenous desferrioxamine and the
recently licensed oral deferiprone, have not been used in this patient group (Porter,
2001; Weinberg, 1999). Desferrioxamine is a siderophore produced by Streptomyces
pilosus, and it is used for iron chelation therapy of patients with iron overload or acute
iron poisoning. The use of desferrioxamine can increase the risk of infections of bacteria
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or fungi that are capable of utilising this siderophore for growth, e.g. bacteremia by
Yersinia enterocolita (Bottone, 1997) or fungal mucormycosis caused by Rhizopus
(Boelaert et al., 1993). Desferrioxamine is also known to have dose related toxicity
(Porter and Huehns, 1989).
2.2 Iron acquisition of Staphylococcus epidermidis
The coagulase negative staphylococcus S. epidermidis is a gram-positive bacterium in
normal skin flora. It is an opportunistic pathogen, and is increasingly found in hospital-
derived blood-stream infections. The wide-spread use of intravascular catheters in
seriously ill and immunocompromised patients, and selection of antibiotic-resistant
strains are factors which have contributed to the increased infection rates (Kloos and
Bannerman, 1994).
The iron acquisition by staphylococci from transferrin has been studied in vitro starting
with the work of Schade (1963), who found that coagulase positive S. aureus was able
to proliferate in normal serum, whereas coagulase negative staphylococci (S. albus)
could not grow in serum without iron supplementation. This suggested that the S.
aureus strains could aquire iron from partially saturated transferrin whereas the other
strains could not. Iron uptake studies using human transferrin labelled with iron isotope
showed that S. aureus acquired iron from transferrin whereas S. epidermidis did not
(Lindsay et al., 1995). The staphylococci have been described to produce at least three
types of siderophores (Trivier and Courcol, 1996) of which staphyloferrin A was shown
to sequester iron from diferric transferrin when grown in vitro (Modun et al., 1998). In
addition to a siderophore mediated uptake mechanism, a bacterial cell-surface protein,
identified as the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), was described to act as a transferrin receptor for S. aureus and S.
epidermidis (Modun et al., 1998; Modun et al., 2000). S. epidermidis grew in the
presence of diferric transferrin and converted transferrin into the iron free form at the
high bacterial concentrations (108 CFU/ml) used in the study (Modun et al., 1998).
3 Methods to produce apotransferrin
Transferrin has been isolated and purified making use of a wide variety of starting
materials and purification methods in laboratory scale preparation. Methods that are
suitable for large scale manufacturing of transferrin have mainly been developed with
the aim to produce transferrin for use in research and in bulk quantities for cell culture
media. Many methods are based on the use of fraction IV from the Cohn cold ethanol
fractionation process for human plasma (Cohn et al., 1946) as starting material, and
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employ ion exchange chromatography for protein purification. Inman et al. (1961) used
the Cohn fraction IV and purified transferrin by use of precipitation and batch ion
exchange adsorption techniques to prepare ≥90% pure, iron-saturated transferrin with a
yield of about 40%. The method of Kistler et al. (1960) comprised a combination of
ethanol and rivanol precipitation to obtain about 85% pure transferrin, followed by
crystallisation to increase purity to 99%. Later methods include specific steps to
inactivate or remove blood-born viruses. β-propiolactone/UV-irradiation was employed
to inactivate viruses after purification by precipitation in a method by Bethke et al.
(1991). Haupt (1993) used pasteurisation in combination with a complexing agent,
either citrate or EDTA, to prepare virus safe apotransferrin. Solvent detergent treatment
in combination with virus removal filtration was used in a method for preparation of
iron-saturated transferrin (Rolf et al., 1997). Rivat et al. (1992) described a single-step
method to produce transferrin with 97% purity and 75% yield from a by-product of a
chromatographic plasma fractionation method that included virus inactivation using the
solvent detergent treatment method (Horowitz et al., 1985).
Recombinant transferrin molecules have been produced in small laboratory scale. These
transferrin products have mainly been used in structural and functional protein analysis.
Full length human transferrin has been produced in BHK cells (Mason et al., 1993) and
in a baculovirus system (Ali et al., 1996). Recombinant N- and C-terminal half
molecules have been expressed in both eukaryotic expression systems (Funk et al.,
1990; Mason et al., 1996; Mason et al., 1997; Mason et al., 2001; Zak and Aisen, 2002)
and prokaryotic systems (Hoefkens et al., 1996).
The transferrin products obtained by the described methods vary with respect to iron
content, protein purity and degree of polymerisation and aggregation, and the yield of
product is often low. For use as a therapeutic agent in iron binding therapy, an
apotransferrin product needs to have a native conformation, it has to be in the iron-free
form, and, it must be safe for intravenous administration. At the same time, the
production method has to be cost effective to enable production of large, up to kilogram,
product quantities .
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AIMS OF THE STUDY
The general objectives were to develop an apotransferrin preparation and study its
biochemical efficacy in iron binding therapy. The specific objectives were:
− to develop an efficient process for manufacturing of virus-safe pharmaceutical
apotransferrin
− to characterise the apotransferrin product
− to evaluate methods for NTBI determination in serum
− to study the binding of NTBI in serum by apotransferrin administration
− to study the dependence of the growth of Staphylococcus epidermidis on NTBI, and
the effect of apotransferrin on the growth of S. epidermidis in patient serum
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MATERIALS AND METHODS
The methods are described in detail in the original publications (I-V) and briefly below.
1 Methods for production, identification and characterisation of
apotransferrin (I)
1.1 Apotransferrin production method
The production of apotransferrin described in publication I was carried out as follows:
Apotransferrin was purified from fraction IV of the Cohn cold ethanol fractionation
method for human plasma, based on the Krijnen modification of Cohn method 6 (Kistler
and Friedli, 1980; Krijnen, 1970). The fraction IV paste was dissolved in water, 5%
PEG was added, and the protein precipitate was removed by depth filtration to obtain a
clarified crude transferrin solution. Cation exchange chromatography using SP
Sepharose was used to capture the proteins, and the transferrin fraction was eluted using
a pH elution. The partially purified transferrin solution was subjected to solvent
detergent (SD) treatment to inactivate enveloped viruses. The main purification step was
the second chromatographic step using Q Sepharose, that also removed the SD-reagents.
The product was diafiltered, and finally virus-filtered using a 15 nm filter. It was
formulated to a 50 g/l protein concentration in a 150 mmol/l sodium chloride solution at
pH 6. The product was sterile filtered and aseptically filled into bottles and stored as a
liquid solution at 2-8 °C or optionally lyophilised. The process flow scheme is shown in
Fig. 3.
1.2 Identification of transferrin
N-terminal sequencing was used for identification of apotransferrin fragments
(Matsudaira, 1987). Peptides for mass mapping were prepared by proteolytic digestions
with endoproteinase LysC on native and deglycosylated apotransferrin after reduction
and alkylation, and desalting by RP-HPLC. The molecular mass of the peptides was
determined by MALDI-TOF mass spectrometry (Vorm et al., 1994).
1.3 Apotransferrin characteristics and purity
The methods used to determine the product characteristics and purity are described in
detail in publication I. Methods especially set up to study transferrin are described here.
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Determination of transferrin iron forms
Urea-polyacrylamide gel electrophoresis (urea-PAGE) for determination of the iron
forms of transferrin was carried out according to an adaptation by Williams et al. (1978)
of the original method of Makey and Seal (1976). Pure transferrin samples of 15-20 µg
were separated in 6% gels (10x10cm) with 6 mol/l urea for 2 h at 170 V constant
voltage. Gels were prepared and run with TBE buffer (0.1 mol/l TRIS, 0.01 mol/l boric
acid, 0.0016 mol/l EDTA, pH 8.4). The gels were stained with Coomassie Brilliant
Blue.
Determination of the iron binding capacity
The iron binding capacity of transferrin was determined by titration with ferric
nitrilotriacetic acid (Welch and Skinner, 1989). 100 µl aliquots of ferric nitrilotriacetate
solution (1-1000 µmol/l) were added to 900 µl samples of apotransferrin (3.3 g/l) in 0.3
mol/l Tris-HCl, pH 8, to give final concentrations of ferric nitrilotriacetate ranging from
0 to 100 µmol/l. After incubation for 1 h at 20-25°C, samples of 350 µl were transferred
to a microtiter plate and the absorbance was measured at 450 nm using a microplate
spectrophotometric reader (Titertek Multiscan RC, Labsystems). The amount of iron
required for full saturation was determined from the inflection point of the absorbance
plot, and the iron binding capacity (%) was calculated by dividing this amount with the
theoretical amount of iron required to fully saturate the added transferrin. The molar
concentration of transferrin was calculated using a molecular mass of 79570 for
transferrin (Morgan, 1992).
Identification of transferrin glycosylation variants
A high resolution ion exchange chromatography method was used to separate
glycosylation variants of transferrin. Samples were injected on to a Mono Q HR 5/5
column (Amersham Biosciences). The equilibration buffer was 0.02 mol/l bis-Tris, pH
6. The transferrin was eluted with a salt gradient in the equilibration buffer from 0 to 0.1
mol/l NaCl in 10 min and 0.1 to 1 mol/l NaCl in 2 min at a flow rate of 1 ml/min.
The protein glycans were removed by enzymatic hydrolysis with N-glycosidase F
followed by purification and desalting of the glycans by chromatography and gel
filtration. The glycans were permethylated and their masses were determined by
MALDI-TOF mass spectrometry (Ciucanu and Kerek, 1984). Electrospray mass
spectrometry was used to study the mass of apotransferrin or of its glycoforms after
separation by IEX-HPLC.
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2 Serum iron parameters (II-V)
2.1 Patient serum samples
Patient serum samples were taken in clinical trials that were approved by the ethical
committee of the Helsinki University Central Hospital and informed written consent of
the patients was obtained.
2.2 Serum iron and transferrin saturation
Serum transferrin was determined by an immunoturbidimetric method. Serum iron was
measured with colorimetric assays without deproteinisation using either ferene-S
(Eskelinen et al., 1983) or ferrozine (Eisenwiener et al., 1979) as the chromogenic
agents. The transferrin saturation was calculated by formula (3):
Serum iron (µmol/l) x 3.98 = Transferrin saturation (%) (3)
Serum transferrin (g/l)
Formula (3) is based on the maximal binding of 2 mol Fe3+ per 1 mol transferrin and a
molecular weight of 79570 for transferrin (Morgan, 1992).
2.3 Determination of serum NTBI
The bleomycin-detectable iron assay by Evans and Halliwell (1994) was the primary
assay for NTBI determination in publications II, III, and V, and it was adopted for a
halved sample size. Additions were done in the following order: 250 µl 1 mg/ml DNA
(Type I DNA from calf thymus, Sigma), 25 µl 1.5 IU/ml bleomycin sulphate (Sigma),
50 µl 50 mmol/l MgCl2, 25 µl of sample, standard or blank and finally 50 µl 8 mmol/l
ascorbic acid (Merck, Germany). A predetermined amount of about 7 µl 25 mmol/l HCl
was added before the sample to adjust the pH of reagent mixture to 7.4. All reagents
except the bleomycin were treated with Chelex (Bio-Rad) to remove excess iron. After
incubation for 1 h at 37° C, 50 µl 0.1 mol/l EDTA, 250 µl 1% (w/v) thiobarbituric acid
(Sigma), and 250 µl 25% (v/v) HCl were added and the mixture was incubated at 80°C
for 20 min for chromogen formation. The pink chromogen complex was extracted with
1.5 ml butanol and the phases were separated by centrifugation. 350 µl of the clear top
phase was transferred to microwell plates and the absorbance was measured at 535 nm
using a microplate reader. The samples were measured in parallel with a corresponding
blank without the addition of bleomycin. The absorbance value of the blank was
subtracted from each sample absorbance value. The reagent blank value was subtracted
from the absorbance values of the standards, and a standard curve with 0.1 to 3 µmol/l
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of iron (Iron atomic absorption standard solution in 1% HCl, Sigma Aldrich) was
calculated for each series. Data was transformed to logarithmic values before
calculation of the standard curve by linear regression in order to give weight to the
standards with a low iron concentration (0.1-1 µmol/l) before fitting the curve.
The chelation method with NTA (Gosriwatana et al., 1999) was used in publications II
and IV. 100 µl 800 mmol/l NTA with pH 7 was added to 900 µl serum and the NTA-
iron complex was recovered by ultrafiltration after 30 min at room temperature. The
iron in the ultrafiltrate was quantified with a colorimetric assay with bathophenantroline
chromogen or by atomic absorption spectrophotometry.
2.4 Determination of transferrin iron forms in serum
To study the transferrin iron forms in serum samples, the serum samples were either
precipitated with rivanol before urea-PAGE, or the transferrin bands were visualised by
immunoblotting after electrophoresis of serum. In both cases, the electrophoresis was
carried out as described for the pure transferrin samples.
To obtain a transferrin fraction, 400 µl of 0.375% (w/v) rivanol (6,9-diamino-2-
ethoxyacridine lactate, Sigma) with 10% (w/v) glycerol in TBE buffer was added to 50
µl of serum and the precipitate was removed by centrifugation (Williams and Moreton,
1980). Samples corresponding to 2 µl of serum were applied to the gel. Proteins were
visualised with Coomassie Brilliant Blue staining.
For immunoblotting, serum samples with about 0.15 µg of transferrin were separated in
10x10 cm gels. Proteins were electroblotted from the gel onto polyvinylidene fluoride
membrane (Immobilon-P, Millipore) in a transfer buffer containing 25 mmol/l Tris, 192
mmol/l glycine and 20% (v/v) methanol. The membrane was treated with 0.5% (v/v)
Tween in PBS over night. Transferrin bands were visualised by immunostaining using
rabbit anti-human transferrin IgG (Dako A/S) as the primary antibody in 1% (w/v) BSA,
0.05% (v/v) Tween 20 in PBS for 2 h at room temperature. The blots were washed three
times with PBS containing 0.05% Tween 20 and incubated with anti-rabbit IgG
conjugated with alkaline phosphatase (Jackson Immuno Research Laboratories Inc) in
1% BSA, 0.05% Tween 20 in PBS for 1 h at room temperature. Following three
additional washes with 0.05% Tween 20 in PBS, the blots were stained with 5-bromo-4-
chloro-3-indolyl phosphate-nitroblue tetrazolium colour development solution
(Immuno-Blot Alkaline Phosphatase Assay kit, Bio-Rad). The reaction was stopped
with 100 mmol/l Na-acetate, pH 5, containing 5 mmol/l Na-EDTA for 5 min. The blots
were washed with distilled water and dried.
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The proportions of the different transferrin iron forms were determined by scanning
with a laser densitometer.
3 Growth of Staphylococcus epidermidis (IV, V)
3.1 Bacterial strains and preparation of inoculum
Two multi-resistant clinical isolates of S. epidermidis (16779 and 19435) from
neutropenic patients with a haematological malignancy and septicaemia and the ATCC
12228 strain (Manassas, VA, USA) were used. Stock cultures were kept frozen at -70°C
and subcultures were made on trypcase-soy agar dishes (bioMérieux, France). The
growth medium was RPMI-1640 (R-7509, Sigma) with 50 mmol/l HEPES buffer, pH
7.4 and 2 mmol/l L-glutamine. The medium was depleted of iron using Chelex-100
resin (Bio-Rad) and supplemented with 10 µmol/l CaCl2 and 100 µmol/l MgCl2. Ferric
nitrilotriacetate (FeNTA) with 3 mmol/l iron was used for iron addition in precultivation
of the strains and for saturating normal serum with iron.
To prepare the inoculum, the strains were cultivated in the iron-depleted RPMI with or
without iron supplementation. The iron-depleted RPMI was used to induce the
siderophore production. The siderophore index of the bacterial cultures was determined
with the Chrome Azurol S liquid assay (Payne, 1994). 10-fold dilutions of the bacteria
in saline were used as inocula.
3.2 Monitoring of growth with pure transferrin
Inocula with and without siderophore induction were used. 50 µl was used to inoculate
250 µl of RPMI containing 2.5 g/l of apotransferrin and different amounts of FeNTA.
The growth was monitored by turbidity measurements every 30 min in microwell plates
for 96 h at 37°C with periodic shaking in a Bioscreen C Microbiology Reader
(Labsystems, Finland). Viable counts were determined by plating on trypcase-soy agar
plates (bioMérieux, France).
3.3 Monitoring of growth in serum samples
The inoculum was cultivated in two passages, the first one in iron replete RPMI and the
second one in iron-depleted RPMI. Serum was buffered with 50 mmol/l HEPES, pH
7.4. 50 µl inoculum was added to 200 µl buffered serum. The growth was monitored by
optical density measurements every 30 min for 24 h at 37°C with periodic shaking in
the Bioscreen C Microbiology Reader. The apparatus was placed in an air-tight chamber
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filled with 5% CO2 to retain the pH and bicarbonate levels of serum. For patient
samples, the extent of growth was calculated from the change in OD during growth by
subtracting the baseline OD from the peak level reached at the end of the growth, and
was expressed as ∆OD. Viable counts were determined by plating on trypcase-soy agar
plates (bioMérieux, France).
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RESULTS
1 Pharmaceutical apotransferrin preparation (I)
1.1 Large scale purification of apotransferrin
In fraction IV, transferrin comprises 20-30% of the total protein and the main impurity
is albumin (approx. 50%). The bulk of the albumin and other impurities were removed
in the flow-through fraction of the first chromatography step, the cation exchange (Fig.
3). By using a pH-dependent elution in this chromatography, no buffer exchange was
needed before the second chromatography, the anion exchange. This chromatography
step was the final purification step. It was preceded by the solvent-detergent (SD) virus
inactivation step and the SD chemicals were removed in this step by extensive column
flushing before elution. In the eluate recovered from the anion exchange step,
apotransferrin with a protein purity of at least 98% was obtained (Fig. 3). Later steps,
including the diafiltration, concentration and the virus removal filtration, did not
significantly increase the protein purity. In the overall process, over 90% of
apotransferrin could be recovered from the dissolved fraction IV solution.
Figure 3. Flow scheme of the apotransferrin manufacturing process and SDS-PAGE purity analysis gel
(non-reduced, Coomassie stained) with samples taken from the purification. Lane 1, dissolved fraction
IV; Lane 2: partially purified apotransferrin after cation exchange; Lane 3: purified apotransferrin after
anion exchange; Lane 4: formulated finished product.
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By dissolving the fraction IV paste in water, the pH of the solution remained at the same
level of pH 5.7 as used in the ethanol precipitation. Evidently due to the low pH and
citrate buffer used for fraction IV precipitation, the iron was mostly dissociated from
transferrin in the dissolved fraction IV. By adding EDTA to the solution and applying
the solution to the first ion exchange at the low pH, iron was effectively removed by the
wash fractions and apotransferrin with a low iron content corresponding to about 0.3%
saturation could be recovered.
The specific virus inactivation and removal steps in the process comprised the SD
treatment, the virus filtration and the PEG precipitation. Virus validation studies showed
that the SD treatment rapidly inactivated the enveloped viruses HIV and BVDV with
>4.7 log10 and >5.1 log10 reduction factors, respectively. The removal of the non-
enveloped parvovirus B19 was studied in spiking experiments using PCR for virus
detection. The results indicated that 3.7 log10 was removed in the PEG precipitation step
and >4.5 log10 in the virus filtration. The virus filtration step could be carried out with
high recovery at a high protein load of 4 kg/m2.
1.2 Identification and characterisation of the apotransferrin product
The first 25 amino acids in the N-terminal sequence of the purified product showed
identity with human transferrin. The identity was also confirmed with mass mapping
with MALDI-TOF of the peptides after cleavage with endoproteinase-LysC, and
revealed over 90% of the expected apotransferrin peptides. Electrospray mass
spectrometry of the protein indicated a mass of the protein of 79556, which is the same
as the calculated mass of 79555.4 of the apotransferrin molecule with two biantennary
disialylated glycans. The mass was calculated from the polypeptide chain (75181.4 Da)
with 19 disulphide bonds (-38 Da), two glycans (2x2224 Da) and glycan linkage (-36
Da). IEX-HPLC was used to separate the transferrin into four peaks. The IEX-HPLC
gave reproducible results for different transferrin batches. The proportions of the main
peaks (peaks 2-4) were 7-9%, 79-83% and 9-12% respectively (Fig. 4). The masses of
the peaks and the glycan structures to which they resembled closely to are presented in
Fig. 4.
For more detailed glycan analysis, glycan chains were enzymatically removed from
apotransferrin and characterised by MALDI-TOF mass spectrometry. Glycan analysis
confirmed the presence of the glycan structures in the IEX-HPLC peaks as predicted by
electrospray mass spectrometry. Glycan analysis also revealed traces of structures
carrying fucose in all IEX-HPLC peaks. Minor oxidation of single amino acids were
found for some of the mass structures. The mass spectrometric studies revealed no
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chemical modifications other than glycosylation and the presence of the predicted
disulphide bonds, except minor oxidation.
The product purity and the protein integrity and conformation was studied for several
production batches. The results indicated here are mean results of four batches. In SEC-
HPLC the product was separated into a major peak of 98.5% corresponding to
transferrin monomer and a minor peak, which corresponded to a molecular size of 180-
290 kDa. The non-monomeric peak contained mainly IgA and IgG and a small amount
of transferrin dimer. No polymers or fragments were found. The product showed a
major band of 76 kDa in SDS-PAGE. The iron binding capacity was between 92% and
96% for different batches. The assay proved reproducible with imprecision CVs of 3%
and 1%, inter- and intra-assay, respectively. The method was used in combination with
urea-PAGE, which showed that the iron-free apotransferrin was fully converted into the
iron-saturated form when iron was added. The iron content of the product was low,
corresponding to approximately 0.3% transferrin saturation. No zinc or aluminium
could be detected. The major plasma-derived impurities were hemopexin (0.6%), IgA
(0.7%) or IgG (0.3%). Protease contaminants (plasmin/plasminogen and prekallikrein
activator) were all below the detection limits of the assays.
Figure 4. Apotransferrin separated into four glycoform peaks by IEX-HPLC. The molecular weight of
apotransferrin in the peaks was measured by electrospray mass spectrometry and the proposed glycan
chains are shown. The symbols for the monosaccharide residues are: (◄) N-acetylneuraminic acid; (□)
galactose; (■) N-acetylglucosamine; (○) mannose and (∇) fucose.
6 7 8 9 10 11 12 13
Time (min)
79556 Da
80210 Da
80365 Da79274 Da
77357 Da
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The stability of the 50 g/l liquid formulation was studied. The most informative assays
to detect changes in the product proved to be the iron binding capacity, the transferrin
iron forms by urea-PAGE, IEX-HPLC and SEC-HPLC. The liquid product proved to be
stable for up to 2 years at refrigerator (2-8°C) and 12 months at room temperature.
Lyophilised formulations were stable for four years at refrigerator temperature. The
finished product was sterile, had a low endotoxin content (<2 IU/ml) and was pyrogen
free according to the European Pharmacopoeia methods.
2 Binding of NTBI with apotransferrin
2.1 Evaluation of assay for measuring NTBI (II)
In the bleomycin assay, the sample and reagent volumes were halved and absorbance
measurements were done in microwell plates. The bleomycin assay proved
reproducible. The imprecision coefficients of variation (CVs) were 7.7% and 8.2%
intraassay and 18.4% and 9.8% interassay for a low (0.2 µmol/l) and a high (1.5 µmol/l)
control, respectively. To study the assay accuracy, ferric nitrilotriacetate (FeNTA) was
added to saturate transferrin in serum and the full saturation point was confirmed by
urea-PAGE. The NTBI was ≥0.1 µmol/l in samples with full saturation. The recovery of
the added iron was only ~33% in samples with full transferrin saturation. The
interference of sample haemolysis was studied. The haemolysis had a clear raising
effect on NTBI, but had no effect on the transferrin saturation or on the total iron. The
degree of haemolysis was studied visually and by haemoglobin determination. In
samples with non-visible haemolysis (haemoglobin 290-645 mg/l) up to 0.07 µmol/l
NTBI could be measured. No interference of ferritin was found when patient samples
containing high ferritin concentrations were studied, nor was the treatment drug
cyclophosphamide found to interfere with the assay. A detection limit of 0.1 µmol/l
could be established based on accuracy studies and on the interference of non-visible
haemolysis.
399 patient serum samples were studied and the NTBI levels were compared with
transferrin saturation values. NTBI (≥0.1 µmol/l) was found only when transferrin
saturation was >80%. When samples with visible haemolysis were excluded, there were
no positive samples with <80% transferrin saturation. The NTBI varied between 0 and
0.97 µmol/l in patient samples without visible haemolysis. The highest NTBI
concentration measured with the bleomycin assay in a haemolysed patient sample was
1.6 µmol/l.
The bleomycin assay was compared with the chelation method for measuring NTBI.
The detection limit of the chelation assay was 1.5 µmol/l and the recovery of iron in
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serum was about 64%. The chelation method gave clearly higher NTBI concentrations
(up to 10-14 µmol/l) than the bleomycin assay (up to 1.27 µmol/l) in 61 samples studied
in parallel. There was no clear correlation between the quantitative results of the two
assays in samples above the detection limit of the respective assays. Due to a low
sensitivity (0.01 AU/µmol/l) of the colorimetric determination of the chelated iron, iron
quantification in the ultrafiltrate was also studied by AAS. The AAS gave similar results
as the colorimetric assay, and verified the higher NTBI concentration compared with the
bleomycin assay. However, the chelation method gave positive results for some samples
also at <80% transferrin saturation. In these samples the partial transferrin saturation
was confirmed by urea-PAGE.
2.2 Binding of NTBI in patient serum (III, V)
Apotransferrin was administered to SCT patients in clinical trials. In the first trial (III), a
single dose of 100 mg/kg was given to six patients three days after the SCT. Serum
samples taken before and after the administration and the serum iron parameters
including NTBI and urea-PAGE were studied. Initially, all patients had serum
transferrin saturation >80% and NTBI in their serum. 15 min after the apotransferrin
injection, serum NTBI had disappeared in all patients and transferrin saturation
decreased to 30-50%. The mean increase in the serum transferrin concentration was
1.95 g/l.
Before apotransferrin administration, only fully saturated diferric transferrin was found
in serum, shown by urea-PAGE. At 15 min after the injection, iron-free and monoferric
forms appeared in the sera of all patients. The amount of the diferric transferrin
remained about the same in five patients but was reduced in one patient. This suggested
that most of the iron bound by the administered apotransferrin represented NTBI and
was not shuttled from the fully saturated endogenous transferrin. At the later time points
the amount of the diferric form increased, while the iron-free form disappeared first and
the monoferric form remained detectable somewhat longer. This indicated that the
administered apotransferrin was first converted into the monoferric form and further
into the diferric form. The conversion occurred at different rates in the individual
patients and coincided with the increase in the calculated transferrin saturation. The
amount of iron bound by the administered apotransferrin during the first 15 min was on
the average 16 µmol/l (range 11-22 µmol/l), when calculated from the amount of
formed monoferric transferrin. This was much higher than the NTBI concentrations
measured by the bleomycin-assay before the administration (0.3 ± 0.1µmol/l, mean ±
SD ) (II).
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NTBI reappeared and the transferrin saturation exceeded 80% 12-48 h after the injection
in four patients and after six days in one patient. NTBI remained non-detectable for the
whole 12-day follow-up period in one patient.
Apotransferrin was also given in repeated doses to twenty patients, starting six days
before the SCT, before the onset of myeloablative conditioning which leads to
appearance of NTBI in patient sera. Three different dosage regimens were studied
during a three-week follow-up period, the total doses per patient were 0.3, 0.6 and 1
g/kg, respectively. With the repeated doses, the occurrence of NTBI could be
completely avoided in 5 of 8 patients who received 1 g/kg of apotransferrin and in one
patient who received 0.3 g/kg. In the other patients, the apotransferrin dosing was not
sufficient to completely prevent full transferrin saturation and NTBI appearance during
the follow-up period.
3 Growth of Staphylococcus epidermidis (IV, V)
The growth of S. epidermidis in serum-free conditions in the presence of pure
transferrin at different saturation levels was studied. The transferrin saturation was
monitored by absorbance measurements and the transferrin iron forms by urea-PAGE.
At low initial bacterial cell densities (102 - 104 CFU/ml), the growth of S. epidermidis
was critically dependent on NTBI and a high transferrin saturation of at least 90%. At
higher initial densities, growth was detected also in the presence of partially saturated
transferrin. The siderophore induction measured as the siderophore index was highest
when the inoculum was precultivated in iron-depleted media. Addition of FeNTA up to
1 µmol/l resulted in a linear decrease of the siderophore index. Induction of siderophore
production during precultivation did not change the growth dependence on NTBI. All
three S. epidermidis strains showed the same dependence on full transferrin saturation
for growth.
In serum, a similar influence of NTBI on growth was detected. In normal serum samples
with iron added to form NTBI and in patient samples with NTBI, S. epidermidis grew
consistently at all inoculated (102 – 105 CFU/ml) cell concentrations. In normal serum,
no growth was detected at inoculated cell densities up to 103 CFU/ml. At higher initial
densities, growth was detected but with a slower rate than in the samples with NTBI.
Addition of apotransferrin to bind NTBI restored the growth inhibitory effect, whereas
addition of holotransferrin did not. Again, the three S. epidermidis strains behaved
similarly.
The ability of S. epidermidis to grow in samples from SCT patients was studied. Using
one of the multiresistant strains, bacteria (103 CFU/ml) were inoculated to serum
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samples and the growth was measured as the increase in OD from baseline to its
maximal level, expressed as ∆OD. The sensitivity of the OD assay to detect growth in
serum samples was verified by viable count measurements. The detection limit for
significant growth corresponded to a ∆OD value of 0.05, which was calculated as 10 SD
above the background ∆OD value of serum samples (n=18) without growth curve. The
threshold density of S. epidermidis which could be detected by the OD determination
was about 106 CFU/ml and thus a positive ∆OD value indicated growth of at least 3
log10 in 24 h.
The bacterial growth studied in 132 patient samples was found to have a close relation
to the presence of NTBI and a high transferrin saturation level (>80%). In samples from
two patients who received no apotransferrin, the bacterial growth was promoted at the
same time as NTBI appeared in serum due to myeolobalative treatment. In three patients
who received a single dose of apotransferrin the growth was prevented simultaneously
as the NTBI was bound by transferrin. The bacteriostatic effect typically disappeared
when NTBI reappeared. A patient who received repeated apotransferrin in high enough
doses to prevent formation of NTBI also had restored bacteriostatic effect in serum
throughout the follow-up period.
Markers for septic infections (fever >38°C, clearly elevated CRP >30 mg/l) were
compared in the patients who did not receive apotransferrin or received repeated doses
of apotransferrin at two different dose levels, 0.3-0.6 g/kg and 1.0 g/kg respectively.
There was a trend, however not statistically significant, towards a lower incidence of
suspected septic infections among the patients who received high apotransferrin doses
compared with the patients who did not receive apotransferrin. The apotransferrin
administrations reduced in a dose-dependent manner the number of days with detectable
NTBI in the patient serum. When the total number of days with positive infection
markers was evaluated as a proportion of all study days, there was a significant
reduction in the number of days with fever and days with elevated CRP in the patient
groups who received low and high doses of apotransferrin, respectively. When both
markers were evaluated together, there was a significant reduction in the high dose
group.
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DISCUSSION
1 Apotransferrin product (I)
The developed manufacturing process enabled production of pure and virus-safe
apotransferrin with high yield and only a few process steps. Transferrin was maintained
in the iron-free apoform from the beginning of the process, and excess iron was
removed in the first ion exchange step. It was therefore not necessary to have a separate
iron-removal step. Apotransferrin was purified by a combination of a cation and a anion
exchange chromatography. Only one ultrafiltration step was needed for concentration
and buffer exchange of the pure apotransferrin solution.
The viral safety of the apotransferrin product was based on reduction of potential virus
load in the starting material by donor selection and testing for infection markers and by
effective virus inactivation and removal during the manufacturing. The major virus
inactivation step in the process was SD treatment, which very reliably inactivates all
enveloped viruses (Horowitz et al., 1993; Pehta, 1996). Virus filtration with a 15 nm
pore size hollow fibre filter effectively removes even the small non-enveloped viruses,
such as HAV and parvovirus (Burnouf-Radosevich et al., 1994). Parvovirus B19
currently remains a problem with plasma products because its level in the starting
plasma may be very high (up to109 gen. eq./ml) and a single virus filtration step may not
be capable of removing the potential virus load from the plasma pools (Siegl and
Cassinotti, 1998). Although clinically significant parvovirus transmissions by plasma
products are apparently very rare, parvovirus transmission might be harmful to immuno-
compromised patients receiving high-dose chemotherapy (Schmidt et al., 2001), who
participated in this study. Therefore, the starting plasma was tested for parvovirus B 19
by PCR as a complementary measure on the overall virus safety. Both PEG
precipitation and 15 nm virus filtration were implemented to the process in order to
achieve two effective removal steps for parvovirus. Considering the potential level of
parvovirus in the plasma pools after PCR screening and the clearance of parvovirus
observed in virus removal studies of the process, it could be concluded that the finished
product was with high confidence safe also with respect to parvovirus transmission.
The structural characterisation indicated that the pure apotransferrin product was
identical with human plasma iron-free transferrin. Electrospray mass spectrometry did
not indicate chemical modifications in the apotransferrin molecule other than the N-
linked glycans and the predicted 19 disulphide bonds, except minor oxidation most
probably of single methionine residues. The identified glycan chains were structurally
closely similar to the structures described before for human plasma transferrin (Fu and
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van Halbeek, 1992). The minor transferrin variant with only one biantennary glycan
chain has not been identified in the earlier studies.
The process yielded a pharmaceutical composition of apotransferrin, which had a purity
of at least 98%, contained mainly monomeric transferrin and had no detectable
polymers or aggregates. Assays were developed for the assessment of the iron binding
capacity and integrity of the pure apotransferrin product, which proved to be sensitive
indicators of the stability of the product. Both the lyophilised formulations and the
liquid formulation proved to have good stability at refrigerator temperature, four and
two years respectively. The developed transferrin assays were also used to study the
quality of the finished product. Results of products from several batches confirmed that
the production method could be carried out with consistent results for the finished
product, which is a prerequisite for a production method of a medicinal product. The
formulation with sodium chloride at pH 6 was suitable for intravenous administration
and the product sterility and process hygiene controls were confirmed by the
pharmacopoeia methods.
Potentially harmful impurities described in other transferrin products include aggregates
and polymers formed during pasteurisation (Haupt, 1993). Presence of high amounts of
process derived aluminium (Rigal et al., 1989) and zinc (Rolf et al., 1997) has been
reported. The product with a high aluminium content was used in a study with three
patients undergoing myeloablative chemotherapy and bone marrow transplantation.
Two of the three patients developed acute renal failure, which may have been associated
with the administration of the high aluminium content of the transferrin preparation.
The study did not demonstrate efficacy of the transferrin preparation in the binding of
free iron in the patients or other benefits, but rather suggested that the therapeutic use of
transferrin may not be safe. As with other plasma derivatives, contaminating plasma
proteases present a further possible cause for adverse effects in patients. However, the
level of all these plasma and process derived impurities was very low in the present
apotransferrin product.
2 Determination of serum NTBI (II, III)
The bleomycin assay evaluation demonstrated that the microwell modification of the
assay could be carried out reproducibly using one-half the amount of reagents and
serum compared with the original assay (Evans and Halliwell, 1994), which made it
possible to study large numbers of patient samples in microwell plates. Sample
haemolysis interfered with the assay, and there was a clear correlation between the
NTBI and the haemoglobin concentrations. An earlier report indicated that pure
haemoglobin does not interfere with the assay (Gutteridge et al., 1981). It is possible,
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that with the mechanical haemolysis studied here other degradation products from
haemoglobin were formed which could have caused the interference. However, the non-
visible haemolysis did not result in false positives when using a detection limit of 0.1
µmol/l, which was also the detection limit which was measured in the accuracy studies.
When the bleomycin assay was compared with the chelation method for measuring
NTBI, it was found that the latter one gave NTBI concentrations that were clearly
higher (max 14 µmol/l) than with the bleomycin assay (max 1.6 µmol/l). Similar NTBI
concentrations in patient samples obtained by the bleomycin assay have been found by
(Carmine et al., 1995), whereas levels of 20-28 µmol/l have been measured by others
(Halliwell et al., 1988; Harrison et al., 1994). The higher total levels were found with an
earlier version of the bleomycin assay (Gutteridge et al., 1981) without the final butanol
extraction step, which apparently reduces the risk of possible interfering compounds in
the spectrophotometric measurement. Using the chelation method the NTBI
concentrations were in a similar range of 0-10 µmol/l as found by others using the same
type of assay (Bradley et al., 1997; Gosriwatana et al., 1999).
It was also found that unlike the bleomycin assay in which positive samples were
detected only when transferrin saturation was >80%, the chelation method detected
NTBI in some serum samples also when the transferrin saturation was <80%. The use of
a chelator to mobilize NTBI in serum samples evidently is a reason for the higher NTBI
levels gained by the chelation-based assay. The chelator probably mobilises iron from
complexes in which it is not available for the bleomycin reagent. 80 mmol/l NTA was
able to mobilise iron from albumin, but also in small amounts from other proteins such
as transferrin (~0.5 µmol/l) and ferritin (~0.3 µmol/l) (Gosriwatana et al., 1999). The
use of the chelating agent could also explain our results of detectable NTBI in serum
samples with <80% transferrin saturation, if the chelating agent had mobilised a small
amount of transferrin-bound iron.
In the patients who received a single apotransferrin dose, the level of NTBI was also
calculated from the amount of iron bound to the administered apotransferrin, based on
the shift of apotransferrin into the monoferric form measured by urea-PAGE 15 min
after the injection. The average level (16 µmol/l) represented about 50% of total serum
iron in the patients, which was slightly higher but in the same order of magnitude as
found by the chelation method. It is possible that the intravenously administered
apotransferrin had the capacity to mobilise NTBI from complexes in the vessel wall.
Such loosely bound iron cannot be measured in serum samples. The vascular walls can
theoretically provide polyanionic sites for NTBI, such as glycosaminoglycan chains of
endothelial surface proteoglycans. Another speculation for the high concentration of
NTBI calculated in the 15 min samples, is that the apotransferrin was able to
immediately sequester low-molecular-weight iron which is released by macrophages
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from degrading erythrocytes (Fillet et al., 1989; Moura et al., 1998). Instead of being at
least partly taken up by the transferrin independent uptake mechanism in parenchymal
and especially liver cells (Craven et al., 1987; Kaplan, 2002), the iron could be directly
bound by the apotransferrin which was available after the infusion.
The results of the different methods to measure NTBI indicate that the bleomycin assay
does not measure the total amount of NTBI. The true concentration of NTBI in serum of
the SCT patients can most likely be in the order of 10 µmol/l, even up to 20 µmol/l, as
measured by the chelation method and calculated as the iron bound to injected
apotransferrin in vivo. However, the bleomycin assay has high specificity and does not
measure ferritin iron, which makes it a useful method to detect NTBI. The NTBI
measured by the bleomycin assay is capable of binding to bleomycin and generating
free radicals and is therefore considered to be a measure of the redox activity of NTBI.
The lower concentrations obtained with the bleomycin assay reflects the heterogeneous
nature of NTBI being a mixture of different iron forms with different affinities for
different chelators (Hider, 2002; Petrat et al., 2002). It could mean that only a portion of
the loosely bound NTBI measured in serum is redox-active and capable of binding to
bleomycin whereas a larger portion can be chelated by NTA.
3 Binding of NTBI by apotransferrin administration (III, V)
In the patients who received single dose injections of apotransferrin, NTBI measured by
the bleomycin assay disappeared from the sera of all patients indicating that it was
effectively bound by the administered apotransferrin. NTBI remained undetectable for a
variable time ranging from a few hours up to several days. In most patients, NTBI
reappeared 12-48 h after the apotransferrin injection. Another indication of iron binding
by the administered apotransferrin was the conversion of transferrin into monoferric and
diferric forms in the sequential serum samples after the apotransferrin injection.
Complete prevention of NTBI during the whole studied SCT period could be achieved
with repeated administrations starting before the onset of the myeloablative treatment.
Apparently no other iron-chelating agents have been studied in SCT patients, but
desferrioxamine has been extensively studied in chronic iron overload diseases such as
hereditary haemochromatosis and thalassemia major. It has been shown that part of the
NTBI in haemachromatosis patients is not effectively chelated with desferrioxamine
(Breuer et al., 2001) and the presence of NTBI in patient sera without full transferrin
saturation has been reported (Aruoma et al., 1988; Gosriwatana et al., 1999; Loreal et
al., 2000). However, our results with the bleomycin assay did not indicate the presence
of NTBI unless transferrin saturation exceeded 80%. The disappearance of bleomycin-
detectable NTBI after the apotransferrin injection indicated that the redox-active iron in
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the serum of SCT patients was in a form that was effectively bound by transferrin. It is
possible that the underlying disease is the reason for the differences in NTBI forms
found in the different patients groups. In haemochromatosis, the NTBI is formed after a
slow accumulation of body iron stores over a long time period of several, even decades
of years. In the haematological patients studied in this work, a halt of erythropoiesis and
release of iron from senescent erythrocytes form the NTBI within hours. It may be, that
the gradual formation and long presence of NTBI in the haemochromatitic patients may
lead to less soluble and perhaps oligomeric iron isoforms that have a low affinity for
transferrin or desferrioxamine (Hider, 2002).
The results indicate the feasibility of using apotransferrin as a natural iron binding agent
for the SCT patients. In contrast to chelation by desferrioxamine, whereby iron is
excreted from the body (Porter, 2001), the recovering erythropoetic cells of the bone
marrow could utilise transferrin-iron after the stem cell transplantation. The clinical
efficacy of the apotransferrin was not within the scope of this work and remains to be
studied in larger patient groups. The results from the biochemical efficacy studied in
this work indicate that doses of apotransferrin of 1 g/kg, or even higher, will be needed
to prevent NTBI formation in the SCT patients.
4 Transferrin, NTBI and the growth of Staphylococcus epidermidis
(IV,V)
In serum free conditions with transferrin, the growth of S. epidermidis was critically
dependent on NTBI and high transferrin saturation for growth. A similar effect was
found when the growth in serum was studied. At inoculated cell densities of 104
CFU/ml and higher, growth could be detected but with a slower growth rate than in
serum samples that had full transferrin saturation and NTBI. When the growth in SCT
patient samples was studied, 80% was found to be a threshold for transferrin saturation,
above which bacteria grew. There was also a strong association between bacterial
growth and NTBI.
Earlier studies of growth of S. epidermidis in serum free conditions have indicated
growth in the presence of iron-saturated transferrin (Lindsay et al., 1995; Modun et al.,
1998), which is in line with the present studies. It was suggested that a cell wall receptor
identified as glyceraldehyd-3-phosphate dehydrogenase (GAPDH) acts as a transferrin
receptor and facilitates iron removal from the receptor-bound transferrin (Modun et al.,
2000). In these studies, high (108 CFU/ml) bacterial densities were used. In our studies,
the inability of the bacteria to grow at low initial densities in the presence of partially
saturated transferrin suggests that iron displacement from transferrin requires high
bacterial concentrations. It is thus possible, that the receptor mediated mechanism to
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scavenge iron from transferrin requires presence of high cell densities, perhaps thereby
forming high concentrations of organic phosphates that might displace iron from
transferrin (Morgan, 1979). The GAPDH receptor-mediated facilitation of iron was
recently questioned in the case of S. aureus by Taylor and Heinrichs (2002). They found
that GAPDH showed no affinity for transferrin, and a new cell wall protein was
described as the transferrin receptor. Unlike the GAPDH, this protein was expressed
only in iron-limiting conditions. The role of GAPDH as a receptor for transferrin in the
staphylococci is therefore probably not fully clarified. It is possible that the role of
GAPDH in iron transport is mainly due to its capability to form the phosphate
compounds that at high concentrations can release iron from transferrin.
The growth of S. epidermidis was studied in samples taken from SCT patients who
received different doses of apotransferrin or no administration. The appearance of NTBI
and loss of growth inhibition coincided when analysed in sequential serum samples
taken after initiation of myeloablative conditioning. Intravenously administered
apotransferrin that effectively bound NTBI also restored the growth inhibition.
Repeated administrations of apotransferrin could in high doses maintain the growth
inhibitory effect during the whole stem cell transplantation period.
Because the ability of S. epidermidis to multiply in serum in the absence of NTBI was
dependent on the initial bacterial density, the initial bacterial count may play a role in
the pathogenesis of septic infections. S. epidermidis often contaminates central venous
catheters, where biofilm formation promotes the adherence and protection of the
bacteria (Kloos and Bannerman, 1994). In stem cell transplant patients, the oral mucosa
is another possible route of infection due to treatment-related mucositis (Kennedy et al.,
2000). In catheter infections, there is an association between the number of organisms
retrieved from the catheter surface and the risk for infection, and infection occurs only
when the number exceeds a certain quantitative threshold (Raad, 1998; Sherertz et al.,
1990). In a study of catheter-related bacteremias, blood drawn from the catheters had up
to 105 CFU/ml of coagulase-negative staphylococci, whereas peripheral blood samples
had 101 – 102 CFU/ml (Flynn et al., 1987). Another study showed that the mean
bacterial cell concentration in peripheral blood samples in blood stream infections
caused by coagulase-negative staphylococci was 33 CFU/ml (Herwaldt et al., 1996). It
may be reasoned, that the high local density of S. epidermidis in the intravenous
catheters promotes bacterial growth also in the absence of NTBI, whereas the
proliferation of the low counts occurring in the peripheral blood may depend on the
availability of NTBI.
Among the small number of patients in the present study, the incidence of septic
infections was not significantly different in the patients who received apotransferrin
than in the control patients. When the patient groups were compared with respect to the
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total number of days with fever or elevated CRP, the patients who received repeated
doses of apotransferrin had significantly less positive days than the patients who did not
receive apotransferrin. Correspondingly, the number of days with intravenous
antibiotics was significantly smaller during the study period in the patients who received
repeated apotransferrin infusions. Although the patients were not compared in a
randomised setting, this suggests that repeated infusions of apotransferrin may have
protected the neutropenic patients against septic infections.
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CONCLUSIONS
A manufacturing method was developed whereby human apotransferrin can be
produced with high recovery from Cohn fraction IV with only a few process steps. The
product has high purity and a native conformation and is suitable for intravenous
infusion. A stable liquid formulation was developed. The production method comprises
virus inactivation and removal steps, which with high confidence contribute to the virus
safety of the product.
The microwell modification of the bleomycin assay for NTBI determination is
reproducible and has a high specificity to detect NTBI in serum samples at >80%
transferrin saturation, when haemolysed samples are excluded. The bleomycin assay
measures redox-active iron, but it underestimates the true concentration of NTBI. The
concentration of NTBI can be calculated from the shift of transferrin iron forms found
in vivo after intravenous infusion of apotransferrin to patients. It can also be determined
with the chelation based method, which, however, has a lower specificity than the
bleomycin method. In the SCT patients, the concentration of NTBI can be as high as 20
µmol/l.
Apotransferrin given in single intravenous doses to six patients bound NTBI effectively,
although in most cases temporarily. With repeated high dose regimens, the appearance
of NTBI could be prevented in 5 of 8 patients.
The opportunistic pathogen S. epidermidis is dependent on NTBI for growth at low
bacterial concentrations. Apotransferrin administered to patients binds NTBI and
restores the growth inhibitory effect of serum. Apotransferrin might protect the patients
against infections by S. epidermidis and other opportunistic pathogens whose growth is
dependent on NTBI.
In conclusion, the apotransferrin is pure and safe and shows in vivo the biochemical
effects that can be expected of a functional human apotransferrin product. In SCT
patients it is possible to prevent the appearance of NTBI and maintain the bacterial
growth inhibitory effect in serum.
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